I'm available for business trips to other cities for projects lasting a month or longer.
Ready to join the revolution in liver disease treatment? We’d love to hear from you!
We will get back to you within 24 hours. By submitting your request, you agree to our Privacy Policy.
ABOUT US
Harnessing the power of AI to revolutionize liver health
Founded in the heart of Silicon Valley (Mountain View, California), Karyon
Bio was born out of a deep commitment to tackling one of the most
pressing health challenges of our time—metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD).
In simple terms, it refers to the buildup of excess fat in the liver in people who drink little to no alcohol. MASLD affects a staggering 30% of the global population, and its symptoms often go undetected until they progress to advanced stages, leading to severe complications such as cirrhosis, liver failure, and even liver cancer. When combined with metabolic dysfunctions, the morbidity associated with MASLD increases exponentially, making early diagnosis and effective management critical.
Karyon Bio is building the next generation of agentic artificial intelligence
(AI) healthcare solutions that transform how complex diseases like MASLD are detected, understood, and managed. Partnering globally with hospitals, genome institutes and research labs, our pioneering AI-driven approach empowers clinicians, researchers, and ultimately patients to achieve desired results faster and more efficiently than ever before in history. It's a bold claim, which is why we encourage you to contact us and
discover for yourself why the future is here today with Karyon Bio.
Bio was born out of a deep commitment to tackling one of the most
pressing health challenges of our time—metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD).
In simple terms, it refers to the buildup of excess fat in the liver in people who drink little to no alcohol. MASLD affects a staggering 30% of the global population, and its symptoms often go undetected until they progress to advanced stages, leading to severe complications such as cirrhosis, liver failure, and even liver cancer. When combined with metabolic dysfunctions, the morbidity associated with MASLD increases exponentially, making early diagnosis and effective management critical.
Karyon Bio is building the next generation of agentic artificial intelligence
(AI) healthcare solutions that transform how complex diseases like MASLD are detected, understood, and managed. Partnering globally with hospitals, genome institutes and research labs, our pioneering AI-driven approach empowers clinicians, researchers, and ultimately patients to achieve desired results faster and more efficiently than ever before in history. It's a bold claim, which is why we encourage you to contact us and
discover for yourself why the future is here today with Karyon Bio.
Mission
To revolutionize liver disease diagnosis and treatment by harnessing the power of AI and multi-omics technologies — providing early, accurate and non-invasive solutions that empower healthcare providers and improve patient outcomes worldwide.
Vision
To lead the global fight against liver diseases by becoming the foremost innovator in AI-driven diagnostics, ensuring early detection and personalized care for all. Join us on our journey as we work to bring hope and healing to those affected by liver diseases, harnessing the power of AI to create a healthier world.
The scientific rationale:
A new frontier in diagnostics
A new frontier in diagnostics
Taking the pain (literally) out of liver disease detection/treatment.
Very approachable
Traditional methods of detecting liver diseases—such as liver
biopsies—are invasive, costly, and carry risks for patients. Moreover, they
often fail to provide comprehensive Read more
Unique solutions demand unique intelligence
By seamlessly integrating multi-omics, imaging, clinical, EHR, and other real-world data, our diagnostic tools offer a holistic view of the molecular underpinnings of MASLD.
This multi-layered approach enables us to detect early biomarkers of
disease, predict its progression, and tailor treatment plans to the unique
needs of each patient.
This multi-layered approach enables us to detect early biomarkers of
disease, predict its progression, and tailor treatment plans to the unique
needs of each patient.
A new type of platform
Our proprietary AI-driven platform leverages advanced machine-learning
algorithms to analyze vast amounts of clinical data, imaging results, and
biomedical literature. There is
no reliance on ‘off-the-shelf’ AI that is not designed for the specific
requirements of combatting liver disease.
This allows us to identify subtle patterns and correlations that might go unnoticed, leading to more precise and timely diagnoses. By doing so, we
empower healthcare providers with the insights they need to intervene
early when treatments are most effective and to monitor the disease with unprecedented accuracy.
.
Technology
A glimpse under the hood
At Karyon Bio, our solutions stand out for their unprecedented precision
and insight into liver health, offering hope to millions worldwide.
and insight into liver health, offering hope to millions worldwide.
We derive data from an array of advanced biological methods, including
single-cell and spatial transcriptomics, iPSC-derived models, 3D organoids,
CRISPR-based functional screens, and microfluidic cell-on-a-chip
platforms.
single-cell and spatial transcriptomics, iPSC-derived models, 3D organoids,
CRISPR-based functional screens, and microfluidic cell-on-a-chip
platforms.
Addressing a complex challenge like fatty liver disease requires diverse expertise. Karyon Bio unites specialists in AI, computational biology, genomics, hepatology, radiology, and liver pathology, creating an “in-house synergy.”
This broad collaboration ensures that our research covers every aspect of disease
biology—from molecular foundations to clinical implementation.
This broad collaboration ensures that our research covers every aspect of disease
biology—from molecular foundations to clinical implementation.
Trust in data-driven solutions is vital in healthcare. Our explainable AI approaches illuminate how predictive models arrive at their conclusions, highlighting influential variables and decision pathways.
This transparency fosters confidence among clinicians, researchers, and patients, ensuring our insights are both valid and actionable.
This transparency fosters confidence among clinicians, researchers, and patients, ensuring our insights are both valid and actionable.
Incorporating electronic health records and patient registries offers a longitudinal, real-world perspective on disease progression.
This comprehensive view refines our models, enabling precise identification of at-risk individuals and informing optimal clinical strategies tailored to diverse patient populations.
This comprehensive view refines our models, enabling precise identification of at-risk individuals and informing optimal clinical strategies tailored to diverse patient populations.
We harness sophisticated approaches capable of unifying and analyzing data from multiple modalities—imaging, omics, clinical, and more—within a single framework.
By capturing the relationships and interactions across these diverse datasets, we can uncover hidden disease patterns and correlations, enabling earlier, more accurate detection of fatty liver disease and more precise, patient-specific interventions.
By capturing the relationships and interactions across these diverse datasets, we can uncover hidden disease patterns and correlations, enabling earlier, more accurate detection of fatty liver disease and more precise, patient-specific interventions.
By integrating multi-omics data and AI, we offer a personalized approach to treatment, identifying the most effective therapies based on each patient’s unique molecular profile.
Our research
Karyon Bio is on a mission to transform how fatty liver disease is detected and managed. By integrating multi-omics, imaging, clinical data, EHRs, and sensor-derived data, we gain a comprehensive view of disease mechanisms. Leveraging our cutting-edge multimodal AI, deep neural networks and machine learning (ML), our teams uncover early biomarkers that open the door to precise, non-invasive diagnostics— empowering
earlier detection, improved prognosis, and targeted therapies.
Through close collaboration with hospitals, biobanks, and other research partners, we harness emerging data-generation approaches—from single-cell and spatial transcriptomics to iPSC-derived models and cell-on-a-chip platforms. These advanced methods enrich our datasets and fuel new discoveries, allowing us to translate biomarker insights into accessible, affordable tests that can fit seamlessly into standard blood panels. This patient-centric strategy reflects our startup’s unwavering commitment to innovate, energize, and redefine the future of liver disease care.
earlier detection, improved prognosis, and targeted therapies.
Through close collaboration with hospitals, biobanks, and other research partners, we harness emerging data-generation approaches—from single-cell and spatial transcriptomics to iPSC-derived models and cell-on-a-chip platforms. These advanced methods enrich our datasets and fuel new discoveries, allowing us to translate biomarker insights into accessible, affordable tests that can fit seamlessly into standard blood panels. This patient-centric strategy reflects our startup’s unwavering commitment to innovate, energize, and redefine the future of liver disease care.
Our team
The smartest people are working every day to change the future of liver disease treatment.
- Srinivas ThirunagariFounder & CEORead more
- Greg TanakaChief AI OfficerRead more
- Robert WongChief Clinical Scientist, Liver Disease & FibrosisRead more
Partners
